What it sells
Developing long-lasting drug formulations 50% faster
Business model breakdown
Buyer: who owns the budget?
UnverifiedFormulation or CMC R&D heads at pharma and biotech.
Trigger: what makes them buy now?
UnverifiedSlow trial-and-error formulation development to hit the target product profile.
Workflow: what inputs become what output?
Enter drug and dosage form, AI suite generates formulation report; or choose parameters in a web interface while the robotic lab builds, tests and uploads data to a cloud portal.
Economics: what it saves and how it charges
Offerings: AI Suite, Cloud Lab, Fee-for-Service and Custom Automation.
Distribution: how it reaches customers
Contact-led ('Get in touch').
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2023 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.